In the modified intent-to-treat population, the rate of post-operative complications at 30 days was 37% in the RAPN arm and 46% in the OPN arm. Patients with intermediate- or high-complexity renal ...

A Danish hearing aid manufacturer will move its Scottish operation to Strathclyde Business Park after agreeing a pre-let which is one of the largest deals of 2025. Ospa – the premium serviced office ...

“Our new facilities at Mercury House will provide a premium quality workspace for our UK operations and support the continued growth of our business.” Did you know with a Digital Subscription to The ...

CEVA, Inc. (NASDAQ: CEVA), the leading licensor of signal processing IP for smarter, connected devices, today announced Oticon, the world's leading innovator of BrainHearing™ technology has licensed ...

OPN-6602 received orphan drug designation for relapsed or refractory multiple myeloma, highlighting its therapeutic potential. The FDA's orphan drug designation offers benefits like tax credits and ...

Anna Baluch is a freelance writer from Cleveland, Ohio. She enjoys writing about a variety of health and personal finance topics. When she's away from her laptop, she can be found working out, trying ...

AMES, Iowa – An innovative collaboration between Iowa State University and the private design firm OPN Architects will result in a unique installation for a recently opened public library in Rudd, ...

But analysts believe that even if the UK’s Competition and Markets Authority does block an acquisition for Cochlear, it would not have a major impact on the medical device company’s earnings future.

Hearing starts in the brain and affects everything between your ears. With hearing loss, the brain doesn’t get the sound information it needs to understand what’s being said and expends more energy ...

New Delhi: The UK's anti-trust regulator said on Monday that hearing device maker Cochlear and Copenhagen-based Demant had denied that the Australian firm's purchase of Demant's hearing implants ...

BRUSSELS - Australian hearing device maker Cochlear's acquisition of Copenhagen-based Demant's hearing implants business Oticon Medical is a significant threat to the European market, EU antitrust ...